Single Nucleotide Polymorphisms (SNPs) of FCγRIIA and FCγRIIIA in Patients with Diffuse Large B-Cell Lymphoma Have No Impact On Treatment Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP with and without Rituximab: Results From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymhoma Study Group (DSHNHL)

被引：0
|
作者：
Ahlgrimm, Manfred
Regitz, Evi [1 ]
Preuss, Klaus-Dieter [1 ]
Grass, Sandra
Poeschel, Viola [2 ]
Kreuz, Markus [3 ]
Pfreundschuh, Michael
机构：
[1] Univ Saarland, Sch Med, Jose Carreras Ctr Immuno & Gene Therapy, Dept Internal Med 1, D-6650 Homburg, Germany
[2] DSHNHL, Homburg, Saar, Germany
[3] IMISE, Leipzig, Germany
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1521 / 1521
页数：1
相关论文
共 50 条
  • [21] The Effect of FcγRIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study
    Buyukkurt, Nurhilal
    Ozcan, Mehmet Ali
    Ergene, Ulku
    Payzin, Bahriye
    Tunah, Sunay
    Demirkan, Fatih
    Ozsan, Hayri
    Piskin, Ozden
    Undar, Bulent
    TURKISH JOURNAL OF HEMATOLOGY, 2015, 32 (02) : 152 - 157
  • [22] The Role of Local Therapy (Surgery or Additive Radiotherapy) in Extranodal Involvement of Diffuse Large B-cell Lymphoma (DLBCL) in the Rituximab Era. Results from the RICOVER-60 Trial of the DSHNHL
    Fleckenstein, J.
    Pfreundschuh, M.
    Ziepert, M.
    Zeynalova, S.
    Both, A.
    Loeffler, M.
    Ruebe, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S544 - S544
  • [23] Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial
    Kuhnl, A.
    Cunningham, D.
    Counsell, N.
    Hawkes, E. A.
    Qian, W.
    Smith, P.
    Chadwick, N.
    Lawrie, A.
    Mouncey, P.
    Jack, A.
    Pocock, C.
    Ardeshna, K. M.
    Radford, J.
    McMillan, A.
    Davies, J.
    Turner, D.
    Kruger, A.
    Johnson, P. W.
    Gambell, J.
    Rosenwald, A.
    Ott, G.
    Horn, H.
    Ziepert, M.
    Pfreundschuh, M.
    Linch, D.
    ANNALS OF ONCOLOGY, 2017, 28 (07) : 1540 - 1546
  • [24] Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group
    Pfreundschuh, Michael
    Poeschel, Viola
    Zeynalova, Samira
    Haenel, Mathias
    Held, Gerhard
    Schmitz, Norbert
    Viardot, Andreas
    Dreyling, Martin H.
    Hallek, Michael
    Mueller, Carsten
    Wiesen, Martin H. J.
    Witzens-Harig, Mathias
    Truemper, Lorenz
    Keller, Ulrich
    Rixecker, Tanja
    Zwick, Carsten
    Murawski, Niels
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (36) : 4127 - U354
  • [25] Rituximab improves outcome in patients with diffuse large B-cell lymphoma (DLBCL) -: Single centre retrospective study
    Belada, D
    Zak, P
    Sykorová, A
    Zavrelová, A
    Smolej, L
    Maly, J
    ANNALS OF ONCOLOGY, 2005, 16 : 178 - 178
  • [26] Non-Hodgkin Lymphomas: Impact of Rituximab on Overall Survival of Patients with Diffuse Large B-Cell and Follicular Lymphoma
    Carlos Jaime-Perez, Jose
    Magdalena Gamboa-Alonso, Carmen
    Vazquez-Mellado de larracoechea, Alberto
    Rodriguez-Martinez, Marisol
    Homero Gutierrez-Aguirre, Cesar
    Javier Marfil-Rivera, Luis
    Gomez-Almaguer, David
    ARCHIVES OF MEDICAL RESEARCH, 2015, 46 (06) : 454 - 461
  • [27] Treatment of High-Grade Diffuse Large B-Cell Lymphoma (HG-DLBCL) of the Elderly with Lenalidomide, Rituximab, Cyclophosphamide, and Prednisone
    Rios, Adan
    Gonzalez, Anneliese
    Dinh, Brian
    Cervoni-Curet, Frances
    Yang, Wei
    Rekoff, Gregg
    Chen, Lei
    Wahed, Amer
    Nghia Nguyen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S268 - S268
  • [28] Bi-weekly dosing preserves the efficacy of rituximab in elderly patients with poor-prognosis DLBCL: Results from the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study group (DSHNHL).
    Schubert, J.
    Reiser, M.
    Wenger, M.
    Kloess, M.
    Lengfelder, E.
    Franke, A.
    Steinhauer, H. B.
    Clemens, M.
    Schmitz, N.
    Loeffler, M.
    Pfreundschuh, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 431S - 431S
  • [29] CNS RECURRENCE IN AGGRESSIVE LYMPHOMA TREATED WITH MODERN CHEMOTHERAPY (CHOP-14) WITH OR WITHOUT RITUXIMAB: AN ANALYSIS OF CNS-EVENTS IN ELDERLY PATIENTS TREATED IN THE RICOVER-60 TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN'S LYMPHOMA STUDY GROUP (DSHNHL)
    Schmitz, N.
    Boehme, V.
    Zeynalova, S.
    Lengfelder, E.
    Reiser, M.
    Steinhauer, H.
    Clemens, M.
    Nickenig, C.
    Loeffler, M.
    Pfreundschuh, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 158 - 158
  • [30] CNS-disease in elderly patients treated with modern chemotherapy (CHOP-14) with or without rituximab: An analysis of CNS events in the RICOVER-60 trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
    Boehme, Volknaar
    Zeynalova, Samira
    Lengfelder, Eva
    Franke, Astrid
    Reiser, Marcel
    Steinhauet, Hans
    Clemens, Michael
    Nickenig, Christine
    de Witt, Maike
    Loeffler, Markus
    Pfreundschuh, Michael
    Schmitz, Norbert
    BLOOD, 2007, 110 (11) : 159A - 160A
12345